Abstract
Many facets of drug discovery involve the use of patented materials and methods, subjecting the researcher to potential liability from infringement of the underlying patents. Enacted in 1984, the Hatch-Waxman Act established a “safe harbor” for activities that would otherwise constitute infringement of a patented invention, if those activities were “solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use, or sale of drugs or veterinary biological products”. This article examines the major court decisions interpreting the scope of the safe harbor and their application to various activities in drug development.
Keywords: Research tools, Merck, AbTox, Eli Lilly, Proveris, Safe Harbor Provision, Hatch-Waxman Act, Federal law, Investigational New Drug Applica-tion, New Drug Ap-plication, Patent Term Restoration Act, Abbreviated New Drug, flurazepam, Federal Food, Drug, and Cosmetic Act, hybridoma tech-nology, FDCA, PHS Act, Federal Circui, FDA regulation, Arg-Gly-Asp, RGD, Merck's preclinical experimentation, ANDA, EMD 121974, v3 receptors, angio-matrigel test, FDA's guidelines, U.S. Patent No. 4,879,237, U.S. Patent No. 4,789,734, IC50 or EC50
Current Topics in Medicinal Chemistry
Title: Drug Discovery and the Impact of the Safe Harbor Provision of the Hatch-Waxman Act
Volume: 10 Issue: 18
Author(s): Susanne H. Goodson
Affiliation:
Keywords: Research tools, Merck, AbTox, Eli Lilly, Proveris, Safe Harbor Provision, Hatch-Waxman Act, Federal law, Investigational New Drug Applica-tion, New Drug Ap-plication, Patent Term Restoration Act, Abbreviated New Drug, flurazepam, Federal Food, Drug, and Cosmetic Act, hybridoma tech-nology, FDCA, PHS Act, Federal Circui, FDA regulation, Arg-Gly-Asp, RGD, Merck's preclinical experimentation, ANDA, EMD 121974, v3 receptors, angio-matrigel test, FDA's guidelines, U.S. Patent No. 4,879,237, U.S. Patent No. 4,789,734, IC50 or EC50
Abstract: Many facets of drug discovery involve the use of patented materials and methods, subjecting the researcher to potential liability from infringement of the underlying patents. Enacted in 1984, the Hatch-Waxman Act established a “safe harbor” for activities that would otherwise constitute infringement of a patented invention, if those activities were “solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use, or sale of drugs or veterinary biological products”. This article examines the major court decisions interpreting the scope of the safe harbor and their application to various activities in drug development.
Export Options
About this article
Cite this article as:
H. Goodson Susanne, Drug Discovery and the Impact of the Safe Harbor Provision of the Hatch-Waxman Act, Current Topics in Medicinal Chemistry 2010; 10 (18) . https://dx.doi.org/10.2174/156802610793176693
DOI https://dx.doi.org/10.2174/156802610793176693 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Controlled Release of Drugs and Bioactive Compounds from Mesoporous Silica Nanoparticles
Current Drug Delivery Inhibition of RAGE Axis Signaling: A Pharmacological Challenge
Current Drug Targets Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management
Current Drug Safety Subject Index To Volume 5
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pharmacogenomics of Human ABC Transporters: Detection of Clinically Important SNPs by SmartAmp2 Method
Current Pharmaceutical Biotechnology Advances in Mitotic Inhibitors for Cancer Treatment
Mini-Reviews in Medicinal Chemistry Exploration of the Medicinal Peptide Space
Protein & Peptide Letters TEM8 Targeted Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Phytochemical Content and Potential Health Applications of Pecan [<i>Carya illinoinensis</i> (Wangenh) K. Koch] Nutshell
Current Topics in Medicinal Chemistry Increased Paternal Age and Child Health and Development
Current Pediatric Reviews Host Innate Immune Responses to Microbial Pathogens
Current Vascular Pharmacology CD36-TSP-HRGP Interactions in the Regulation of Angiogenesis
Current Pharmaceutical Design Analysis of Carcinogenic Polycyclic Aromatic Hydrocarbons (PAHS): An Overview of Modern Electroanalytical Techniques and their Applications
Current Drug Delivery Prodigiosins as Anti Cancer Agents: Living Upto Their Name
Current Pharmaceutical Design Epigenetic Regulation and Promising Therapies in Colorectal Cancer
Current Molecular Pharmacology Evaluation of Melatonin Effect on Human Breast Cancer Stem Cells Using a Threedimensional Growth Method of Mammospheres
Anti-Cancer Agents in Medicinal Chemistry GPR55 and its Interaction with Membrane Lipids: Comparison with Other Endocannabinoid-Binding Receptors
Current Medicinal Chemistry NHE-1: A Promising Target for Novel Anti-cancer Therapeutics
Current Pharmaceutical Design Photodynamic Therapy using Carbohydrate Conjugated Porphyrins
Drug Design Reviews - Online (Discontinued) In Vitro Anticancer Evaluation of Some Synthesized 2H-Quinolinone and Halogenated 2H-Quinolinone Derivatives as Therapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry